Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000117 · ClinicalTrials.gov registry record · Phase 3
Intravenous Immunoglobulin Therapy in Optic Neuritis
A Phase 3 study, sponsored by National Eye Institute (NEI).
- Completed
- Registry status
- Phase 3
- Development phase
NCT00000117 is a Phase 3 study that has completed, run by National Eye Institute (NEI).
The verdict
NCT00000117, a Phase 3 study, has completed, sponsored by National Eye Institute (NEI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
To determine whether high-dose intravenous immunoglobulin (IVIg) is more effective than placebo in restoring lost visual function (visual acuity) in optic neuritis (ON). To determine the time course of recovery following IVIg administration. If the reports of IVIg-associated clinical improvement occurring within 3 to 6 months following treatment can be confirmed, this would provide indirect evidence that IVIg may promote central nervous system (CNS) remyelination in optic neuritis and multiple sclerosis (MS).
Interventions
- DRUG Immunoglobulin
Trial Details
| Field | Value |
|---|---|
| Start Date | 1995-08 |
| Est. Completion | 1997-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000117
The ClinicalTrials.gov registry entry for NCT00000117 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Eye Institute (NEI), which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Immunoglobulin is the first listed.
NCT00000117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000117 about?
NCT00000117 is a clinical study titled "Intravenous Immunoglobulin Therapy in Optic Neuritis". To determine whether high-dose intravenous immunoglobulin (IVIg) is more effective than placebo in restoring lost visual function (visual acuity) in optic neuritis (ON). To determine the time course of recovery following IVIg administration. If the reports of IVIg-associated clinical improvement oc...
What is the current status of trial NCT00000117?
This trial is currently completed. It is a Phase 3 study. The study started on 1995-08. Estimated completion is 1997-12.
What interventions are being tested in trial NCT00000117?
The interventions under investigation include: Immunoglobulin (DRUG).
Who is sponsoring clinical trial NCT00000117?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.